glp-1 law firm Agenda glp1 #pharma | Groom Law

PS-IPW analysis showed no significant differences in BP outcomes or target achievement rates according to the preceding treatment

doi: 10.1056/NEJMoa1504720 4 NealBPerkovicVMahaffeyKWde ZeeuwDFulcherGEronduNet al

Another investigation involving 7.5 grams of allulose administered before a meal showed trends toward elevated GLP-1 concentrations, but these findings did not consistently reach statistical significance across all measured time points

Potential implications of the new pharmacotherapies on obesity management The mean WL in clinical trials with the most efficacious new obesity pharmacotherapies ranges between 15% and 25% at 1 year (and it may be even higher for some agents that have not reached weight plateau at study completion)

Conclusion: Early initiation of GLP-1 receptor agonists in patients with diagnosed T2DM was associated with a modest reduction in overall cancer risk, particularly among individuals with obesity

The health implications of these changes run deep